CRNX
Price
$31.39
Change
+$0.77 (+2.51%)
Updated
Apr 2 closing price
Capitalization
2.92B
35 days until earnings call
MREO
Price
$2.37
Change
+$0.20 (+9.22%)
Updated
Apr 2 closing price
Capitalization
376.83M
41 days until earnings call
Ad is loading...

CRNX vs MREO

Header iconCRNX vs MREO Comparison
Open Charts CRNX vs MREOBanner chart's image
Crinetics Pharmaceuticals
Price$31.39
Change+$0.77 (+2.51%)
Volume$1.16M
Capitalization2.92B
Mereo BioPharma Group
Price$2.37
Change+$0.20 (+9.22%)
Volume$1.57M
Capitalization376.83M
CRNX vs MREO Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. MREO commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and MREO is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (CRNX: $31.39 vs. MREO: $2.37)
Brand notoriety: CRNX and MREO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 117% vs. MREO: 129%
Market capitalization -- CRNX: $2.92B vs. MREO: $376.83M
CRNX [@Biotechnology] is valued at $2.92B. MREO’s [@Biotechnology] market capitalization is $376.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileMREO’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • MREO’s FA Score: 1 green, 4 red.
According to our system of comparison, MREO is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while MREO’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 4 bearish.
  • MREO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CRNX and MREO are a good buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а -9.04% price change this week, while MREO (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.26%. For the same industry, the average monthly price growth was -7.43%, and the average quarterly price growth was -11.99%.

Reported Earning Dates

CRNX is expected to report earnings on May 08, 2025.

MREO is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (-5.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.92B) has a higher market cap than MREO($377M). MREO YTD gains are higher at: -32.286 vs. CRNX (-38.607). MREO has higher annual earnings (EBITDA): -43.41M vs. CRNX (-336.07M). CRNX has more cash in the bank: 1.35B vs. MREO (80.5M). MREO has less debt than CRNX: MREO (6.68M) vs CRNX (51.7M). CRNX (1.04M) and MREO (1M) have equivalent revenues.
CRNXMREOCRNX / MREO
Capitalization2.92B377M775%
EBITDA-336.07M-43.41M774%
Gain YTD-38.607-32.286120%
P/E RatioN/AN/A-
Revenue1.04M1M104%
Total Cash1.35B80.5M1,682%
Total Debt51.7M6.68M774%
FUNDAMENTALS RATINGS
CRNX vs MREO: Fundamental Ratings
CRNX
MREO
OUTLOOK RATING
1..100
5811
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
6390
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
8987
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (77) in the null industry is in the same range as CRNX (89) in the Pharmaceuticals Major industry. This means that MREO’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (63) in the Pharmaceuticals Major industry is in the same range as MREO (90) in the null industry. This means that CRNX’s stock grew similarly to MREO’s over the last 12 months.

CRNX's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as MREO (98) in the null industry. This means that CRNX’s stock grew similarly to MREO’s over the last 12 months.

MREO's Price Growth Rating (87) in the null industry is in the same range as CRNX (89) in the Pharmaceuticals Major industry. This means that MREO’s stock grew similarly to CRNX’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that MREO’s stock grew significantly faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXMREO
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GBFAX13.640.11
+0.81%
VanEck Emerging Markets A
FUEPX55.620.16
+0.29%
American Funds Europacific Growth 529F2
RRRCX22.34N/A
N/A
DWS RREEF Real Estate Securities C
GCTRX44.36N/A
N/A
Goldman Sachs US Tax-Managed Eq R6
IRSAX14.95N/A
N/A
Macquarie Real Estate Securities A

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with ELVN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then ELVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+2.51%
ELVN - CRNX
51%
Loosely correlated
+5.19%
TRDA - CRNX
49%
Loosely correlated
+0.46%
DNLI - CRNX
49%
Loosely correlated
+11.80%
INZY - CRNX
48%
Loosely correlated
+6.48%
IDYA - CRNX
48%
Loosely correlated
+10.70%
More